Protagonist Therapeutics, Inc

Protagonist Therapeutics is an integrated biopharmaceutical company focused on discovering and developing differentiated peptide-based medicines. The company organizes its research across three core therapeutic segments: inflammation and immunology, hematology, and metabolic diseases. Key development-stage assets include icotrokinra for plaque psoriasis, rusfertide for polycythemia vera, and preclinical candidates targeting obesity and related conditions. Operating primarily through strategic partnerships, Protagonist collaborates with major multinational pharmaceutical corporations such as Janssen Biotech and Takeda Pharmaceuticals for Phase 2 and Phase 3 development, regulatory submissions, and commercialization.

The company engages in clinical development and regulatory activities spanning the United States and Europe, supported by worldwide licensing and collaboration structures. Its late-stage candidates have been submitted for regulatory review to both the U.S. Food and Drug Administration and the European Medicines Agency. The provided text does not state the company's headquarters location or the physical count of its operating facilities.

Summary of the business section of Protagonist Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, our total global workforce consisted of 132 full-time equivalent employees, 103 of whom were in research and development.”